Clinical trials: Cardiovascular Outcome
Chronic Kidney Disease, Cardiovascular Disease
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
The purpose of this randomized clinical trial is to determine if lowering homocysteine levels in renal transplant recipients with a multivitamin will reduce the occurrence of cardiovascular disease outcomes.
- Conditions
- Chronic Kidney Disease, Cardiovascular Disease, Death
- Trial name
- FAVORIT (NCT00064753)
- Testing
- High Dose Multivitamin, Low Dose Multivitamin
- Where
- 30 sites in United States, Brazil and 1 more
- Volunteers
- 4,110 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Heart Failure
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)
The aim of the study is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.
- Trial name
- NCT03057977
- Testing
- Empagliflozin
- Where
- 520 sites in United States, Argentina and 18 more
- Volunteers
- 3,730 people
- Sponsor
- Boehringer Ingelheim
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)
This phase II MATCH treatment trial tests how well copanlisib works in treating patients with cancer that has certain genetic changes.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06400238
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Heart Failure
The His Optimised Pacing Evaluated for Heart Failure Trial (HOPE-HF).
This is a multi-centre, prospective randomised double-blinded cross over study, recruiting a sub-population of patients with heart failure.
- Trial name
- HOPE-HF (NCT02671903)
- Testing
- Pacemaker: AV optimised, His pacing.
- Where
- 15 sites in United Kingdom
- Volunteers
- 198 people
- Sponsor
- Imperial College London
Traumatic Brain Injury
Prehospital Tranexamic Acid Use for Traumatic Brain Injury
Primary aim: To determine the efficacy of two dosing regimens of TXA initiated in the prehospital setting in patients with moderate to severe TBI (GCS score ≤12).
- Trial name
- TXA (NCT01990768)
- Testing
- 1 gram Tranexamic Acid (TXA), 2 grams TXA, 0.9% Sodium Chloride injectable
- Where
- 12 sites in United States, Canada
- Volunteers
- 967 people
- Sponsor
- University of Washington
Stroke, Shoulder Injury
STRIPS: Shoulder Taping Reduces Injury and Pain in Stroke
Background and Rationale: The most commonly seen disabilities in stroke patients are shoulder injuries such as shoulder pain, glenohumeral subluxation, spasticity of shoulder muscles, soft-tissue trauma, rotator cuff tears, and…
- Trial name
- STRIPS (NCT01062308)
- Where
- 2 sites in India
- Volunteers
- 162 people
- Sponsor
- Christian Medical College and Hospital, Ludhiana, India
Ventricular Tachycardia, Ventricular Fibrillation
Septal - Success Rate and Clinical Outcome of Septal Implant of Ventricular Defibrillation Lead
The purpose of this study is to determine the safety and efficacy of the implant of a ICD lead of defibrillation in the septum of the right ventricle
- Trial name
- NCT00180297
- Testing
- Endotak Reliance G
- Where
- 18 sites in France
- Volunteers
- 215 people
- Sponsor
- Boston Scientific Corporation
Cardiomyopathy
The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy
Open-label, multicenter, international, single-treatment study designed to determine TTR stabilization as well as Fx-1006A safety and tolerability, and its effects on clinical outcomes in patients with V122I or wild-type TTR…
- Trial name
- NCT00694161
- Testing
- Fx-1006A
- Where
- 6 sites in United States
- Volunteers
- 35 people
- Sponsor
- Pfizer
Pulmonary Arterial Hypertension
Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)
COMPASS-2 is a Phase 4, prospective, randomized, double-blind, placebo-controlled, event-driven study evaluating the effect of bosentan on the time to first confirmed morbidity/mortality event in patients with symptomatic PAH…
- Trial name
- Compass-2 (NCT00303459)
- Testing
- bosentan
- Volunteers
- 334 people
- Sponsor
- Actelion
Heart Diseases, Heart Transplantation
Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens
The purpose of this study is to assess the safety and efficacy of tacrolimus in de novo heart transplantation.
- Trial name
- NCT00157014
- Testing
- Tacrolimus, Cyclosporine, Mycophenolate mofetil
- Where
- 13 sites in United States, Canada
- Volunteers
- 111 people
- Sponsor
- Astellas Pharma Inc
Bradyarrhythmia
Clinical Outcome of Pacemaker paTIents According to Pacing Modality and Primary INDications
The study objective is to collect mid-term clinical outcome in a group of patients implanted with permanent pacemaker (PM) according to real-life clinical practice in a multicenter and international environment.
- Trial name
- OPTI-MIND (NCT00976482)
- Where
- Germany
- Volunteers
- 1,745 people
- Sponsor
- Boston Scientific Corporation
Stroke, Acute, Ischemic Stroke
Maimonides Minocycline in Stroke Study
The goal of this study is to determine if oral Minocycline's proposed neuroprotective effects further improve the clinical outcomes, including mortality, of acute stroke patients beyond the current standard stroke care in a large…
- Conditions
- Stroke, Acute, Ischemic Stroke, Hemorrhagic Stroke, Mortality
- Trial name
- NCT06107725
- Testing
- Minocycline
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Maimonides Medical Center
Acute, Non-traumatic Subarachnoid Hemorrhage, Intraparenchymal Hemorrhage
Normoglycemia and Neurological Outcome
Brain injury patients who meet defined criteria will be assigned to intensive insulin treatment (target blood glucose levels of 10-110 mg/dl) or conventional IV insulin treatment (target glucose of 150-170 mg/dl).
- Conditions
- Acute, Non-traumatic Subarachnoid Hemorrhage, Intraparenchymal Hemorrhage, Brain Injuries
- Trial name
- NCT01137773
- Testing
- Insulin, Conventional insulin treatment
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of Louisville
Congenital Heart Disease
Stress Response and Neurodevelopmental Outcome After Cardiac Surgery Utilizing CPB in Children: A Prospective, Double Blinded and Randomized Study
The overall goal of this project is to determine the role of anesthetic management in children undergoing cardiac surgery utilizing CPB in the setting of fast tracking and early extubation.
- Trial name
- NCT02492269
- Testing
- Dexmedetomidine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Aymen N Naguib
Heart Failure
A Study of Ponsegromab in People With Heart Failure
The primary purpose of this clinical trial is to compare the effects of study medicine (Ponsegromab/PF-06946860) with a placebo (an injection that looks like the study medicine but does not contain the active medicine) to find…
- Trial name
- GARDEN TIMI 74 (NCT05492500)
- Testing
- Main cohort (Cohort A): Ponsegromab low dose, Main cohort (Cohort A): Ponsegromab medium dose, Main cohort (Cohort A): ponsegromab high dose
- Where
- 122 sites in United States, Australia and 9 more
- Volunteers
- 455 people
- Sponsor
- Pfizer
Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure
The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction
- Trial name
- DAPA-HF (NCT03036124)
- Testing
- Dapagliflozin
- Where
- 419 sites in United States, Argentina and 18 more
- Volunteers
- 4,744 people
- Sponsor
- AstraZeneca
Sleep Apnea, Obstructive, Stroke
Stroke and CPAP Outcome Study 2
Obstructive sleep apnea (OSA) is associated with impaired stroke recovery. Treatment with continuous positive airway pressure (CPAP) may prevent this but is limited by poor adherence.
- Conditions
- Sleep Apnea, Obstructive, Stroke, Patient Adherence
- Trial name
- SCOUTS2 (NCT02809430)
- Testing
- Continuous Positive Airway Pressure
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Washington
Congestive Heart Failure
Oxidative Stress Markers and Cardiac Resynchronization Therapy (CRT) Outcomes
This is a research study that is evaluating blood markers which may predict which patients who receive CRT will improve. Congestive heart failure (CHF) is associated with increased oxidative stress, a condition where abnormal…
- Trial name
- NCT01151553
- Testing
- CRT Therapy
- Volunteers
- 5 people
- Sponsor
- Emory University
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome
Among adult individuals with type 2 diabetes mellitus and at risk for heart failure with impaired relaxation of the heart mildly reduced kidney filtration function (Type 4 cardiorenal syndrome) this trial will evaluate the…
- Conditions
- Type 2 Diabetes Mellitus, Chronic Kidney Disease, Left Ventricular Diastolic Dysfunction
- Trial name
- NCT02251431
- Testing
- BYDUREON
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Baylor Research Institute
Diabetes Mellitus, Non-Insulin-Dependent
The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)
The primary objectives of the ORIGIN study were: To determine whether insulin glargine-mediated normoglycemia can reduce cardiovascular morbidity and/or mortality in people at high risk for vascular disease with either Impaired…
- Trial name
- ORIGIN (NCT00069784)
- Testing
- insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), reusable pen device for insulin injection
- Where
- 40 sites in United States, Argentina and 38 more
- Volunteers
- 12,537 people
- Sponsor
- Sanofi